
Farid Jalali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10766148/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gold Nanoparticles as Radiation Sensitizers in Cancer Therapy. Radiation Research, 2010, 173, 719.	0.7	547
2	Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy and Oncology, 2005, 76, 168-176.	0.3	172
3	A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiotherapy and Oncology, 2008, 88, 258-268.	0.3	130
4	Defective DNA Strand Break Repair after DNA Damage in Prostate Cancer Cells. Cancer Research, 2004, 64, 8526-8533.	0.4	108
5	Evidence for the Direct Binding of Phosphorylated p53 to Sites of DNA Breaks In vivo. Cancer Research, 2005, 65, 10810-10821.	0.4	98
6	Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Molecular Cancer Therapeutics, 2009, 8, 203-213.	1.9	95
7	Homologous recombination and prostate cancer: A model for novel DNA repair targets and therapies. Radiotherapy and Oncology, 2007, 83, 220-230.	0.3	67
8	Late Residual γ-H2AX Foci In Murine Skin are Dose Responsive and Predict Radiosensitivity <i>In Vivo</i> . Radiation Research, 2010, 173, 1-9.	0.7	59
9	Microscopic imaging of DNA repair foci in irradiated normal tissues. International Journal of Radiation Biology, 2009, 85, 732-746.	1.0	51
10	Expression of Different Mutant p53 Transgenes in Neuroblastoma Cells Leads to Different Cellular Responses to Genotoxic Agents. Experimental Cell Research, 2002, 275, 122-131.	1.2	18
11	WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Molecular Cancer Therapeutics, 2008, 7, 980-992.	1.9	15
12	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal, 2011, 5, e31-e35.	0.3	13
13	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal, 2013, 5, 31.	0.3	0